The first vaccine against COVID-19 tested in the United States is moving into its final phase with promising results, according to results published Tuesday in the New England Journal of Medicine.

Moderna Inc. in collaboration with the National Institutes of Health started working together and within six weeks had a vaccine called mRNA-1273, said Dr. Nadine Rouphael, one of the authors on the study.

"To be able to publish preliminary results three months later is really unprecedented," Rouphael said. "It had shown that the vaccine was well tolerated. It has also shown that the vaccine is able to induce a good immune response."

Ahead of President Donald Trump's visit to the Atlanta area on Wednesday, prominent Georgia Democrats have scheduled a news conference to "slam" what they call the president's "failed coronavirus response," the group announced in a press release.

For state Republican leaders, the visit offers an opportunity to showcase Trump before the GOP base as the November election approaches.

The Trump administration has rescinded a rule that would have required international students to transfer schools or leave the country if their colleges hold classes entirely online this fall because of the coronavirus pandemic.

U.S. Immigration and Customs Enforcement announced the decision as a court hearing was getting underway on a challenge to the rule by Harvard University and the Massachusetts Institute of Technology.